Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 3 2013 09 15 1 8 Mona Kargar Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Alireza Ahmadvand Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Milad Ahmadvand Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Molouk Hadjibabaie Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Kheirollah Gholami Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Seyed Hamid Khoee Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Mohammad Reza Javadi Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Ardeshir Ghavamzadeh Hematology-Oncology and SCT Research Centre, Department of Hematology-Oncology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2015 10 14 Background: Invasive fungal infections (IFIs) are chief infectious complications in patients undergoing hematopoietic stem cell transplantation (HSCT). However, the diagnosis of fungal infections is difficult, and often empiric treatment initiates. Since there is no data available on the prevalence of antifungal drugs administration in allogeneic HSCT recipients in Iran, we decided to conduct this study. Methods: This study was a retrospective review of records of patients who received allogeneic HSCT in the Hematology-Oncology, Bone Marrow Transplantation center at Shariati Hospital in Tehran, between August 2009 and August 2010. Results: Sixty (73.1%) patients consist of 41 men (68.3%) with mean age of 26.3 (± 1.2) years received allogeneic HSCT. Patients received prophylaxis with fulconazole however; in 28 patients (46.7%) it was switched to low dose amphotericin B. Fifteen patients (25%) received treatment with antifungal agents. Amphotericin B was the empiric agent administered. In 3 patients treatment was switched to voriconazole. Neither positive culture nor direct microscopic evidence was available from the obtained specimen. Only in one patient the result of serum galactomannan assay was positive. There were no significant differences in neutropenia duration (P value: 0.54), length of hospital stay (P value: 0.27) and number of patients developed graft versus host disease (P value: 0.07) between patients received antifungal agents with those who did not receive treatment. Conclusion: In this study HSCT recipients received antifungal agents for prophylaxis. Twenty five percent of patients received treatment with antifungal agents empirically. Improvement in diagnosis of these infections can be helpful and lead to targeted therapy. We suggest larger prospective trials for better assessment of antifungal agent administration. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/451 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/451/346

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 3 2013 09 15 9 14 Mehrdad Payandeh Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Dariyush Raeisi Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Nasrollah Sohrabi Department of Medical Laboratory Sciences, Para medicine Faculty, Kermanshah University of Medical Sciences, Kermanshah, Iran. Mohammad Erfan Zare Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. Atefeh Nasir Kansestani Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. Nazanin Keshavarz Student research committee, Shiraz University of Medical Sciences, Shiraz, Iran. Samira Gholami Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. Amir Hossein Hashemian Department of Biostatistics, Faculty of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran. 2015 10 14 Introduction: ITP is an autoimmune blood disorder in which platelet destruction is mediated by anti-platelet antibodies. The mechanisms of anti-platelet antibodies development are still a little known. The rate of some bacterial or viral agents in cause of ITP is well known. Recently, some study proposed that H pylori infection may be associated with ITP and H pylori eradication can improves platelet counts in infected ITP patients. Materials and Method: A baseline platelet count <50×103 µL for 4 weeks prior to study entry were required. These patients were tested for H. pylori infection by urea breath. All positive H pylori patients received triple therapy for 7 or 14 days to eradicate H pylori infection. These patients followed for six months. Results: Of 92 patients with ITP, H pylori infection was found in 59.7% (55/92). After excluding patients with confounding factors, 41 patients were remained. After H pylori eradication, CR wasn’t obtained in any patients. Partial response were obtained only in 3 (7.3%) of the 41 patients and no response in 38 (92.6%) patients. There is a significant difference between the platelet counts of PR and NR groups (P<0.001).  Conclusion: the results of this study and our previously study showed H pylori eradication therapy has beneficial effect for patients with mild thrombocytopenia but the chance of obtaining a response by H pylori treatment is lower in patients with severe thrombocytopenia. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/450 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/450/347

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 3 2013 09 15 15 20 Zohreh Sanaat Tabriz University of Medical Science, Tabriz, Iran. Monireh Halimi Tabriz University of Medical Science, Tabriz, Iran. Morteza Ghojezadeh Tabriz University of Medical Science, Tabriz, Iran. Amir Hossein Pirovi Tabriz University of Medical Science, Tabriz, Iran. Jalil Vaez Gharamaleki Tabriz University of Medical Science, Tabriz, Iran. Ali Esfahani Tabriz University of Medical Science, Tabriz, Iran. Iraj Aswadi Kermani Tabriz University of Medical Science, Tabriz, Iran. Jamal Eivazi Ziae Tabriz University of Medical Science, Tabriz, Iran 2015 10 14 Introduction: Gastric cancer remains the second most common cause of cancer-related deaths worldwide. In many malignancies like, lung and breast, multiple prognostic factors are known, such as mutations in Ki-67, HER-2/neu, p53. In this study, we evaluated immunohistochemical protein expression patterns of cell-cycle-regulators p53, proliferation marker Ki-67, surface expression of CD44, HER-2/neu oncogene proposed as useful prognostic factors. Methods: In this descriptive-analytic study, we evaluate 100 patients with gastric cancer who were referred to Shahid Ghazi Hospital or other oncology clinics of Tabriz University of Medical Sciences in 2005-2010. Patients with pathologic confirmation of gastric cancer were selected. Expression of p53, ki-67, CD-44, HER-2/neu were detected by immunohistochemical staining. Results: In this study, 100 patients with gastric cancer participated. 76(76%) were men and 24(24%) were women with mean age of 64.02(8.05) years. Seventy two samples were intestinal type and 28 were diffuse type. CD44 was positive in 27(27%) patients. P53 was positive in 35(35%) patients. Ki-67 was positive in 53(53%) patients. HER-2/neu was positive in 51(51%) patients. Conclusion: The frequency of positive p53, Ki-67, CD44 and HER-2/neu varied in different studies. Positive Ki-67 and HER-2/neu were not associated with changes in survival but positive p53 and CD44 were significantly associated with improved survival. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/449 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/449/348

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 3 2013 09 15 21 24 Mohamad Ali Mashhadi Genetic of Non communicable disease research center, Zahedan University of Medical Sciences, Zahedan, Iran. 2015 10 14 Introduction: There have been many reports and papers on deficient, normal and high levels of copper in patients with thalassemia major. The aim of this study is to evaluate copper status in a series of more than 300 patients with thalassemia major and determine the degree of copper deficiency or excess. Methods: Three hundred and seventy patients with thalassemia major over 5 years of age were enrolled in this study. All patients were asked to fast for 12 hours before the test. Measurement was performed using atomic-absorption spectrophotometer in 2012 in southeast of Iran. Results: The study included both males (n=192) and females (n=141). Of whom, 90 (27%) were aged 5-10 yrs, 80 (24%) were aged 10-15 yrs and 49% were above 15 years of age. Iron chelation therapy was dessferroxamine, deferasirox and dessferroxamine and deferiprone combinations in 61.5 %( 204 cases), 24.2%( 82 cases) and 14.3%( 47 cases), respectively. Among the 370 cases, 107 (32.1%) had copper deficiency, 73 (21.9%) had copper excess and 153 (45.9%) had normal copper level. Conclusion: High percentage of copper deficiency was documented in 333 patients with thalassemia major and about 50% of patients had normal copper level. This finding showed the importance of micronutrient measurement in thalassemic patients for treatment planning in every part of the world. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/448 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/448/349

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 3 2013 09 15 25 33 Vahid Zamanzadeh PhD, MScN, BScN (Associate professor) Nursing and Midwifery Faculty, Tabriz University of Medical Sciences, Tabriz, Iran. Leila Valizadeh PhD, MScN, BScN (Assistant Professor) Nursing and Midwifery Faculty, Tabriz University of Medical Sciences, Tabriz, Iran. Leila Sayadi PhD candidate, MScN, BScN, Student in Nursing, Students' Research Committee, Nursing & Midwifery Faculty, Tabriz University of Medical Sciences, Tabriz, Iran. Fariba Taleghani PhD, MScN, BScN (Associate professor) Nursing and Midwifery care research center, Nursing and Midwifery Faculty, Isfahan University of Medical Sciences, Isfahan, Iran. Alireza Jeddian PhD, MD, Hematology-Oncology and stem cell transplantation research center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2015 10 14 Background: This study explored the state of hematopoietic stem cell transplantation (HSCT) recipient patients and problems experienced by them and nurse about these state and problems, in Iran. Methods: Qualitative content analysis was used for analyzing semi-structured interviews with 12 HSCT recipient patients and 18 nurses. Results: Three main categories described the HSCT state and problems: shadow of death, living with uncertainty, and immersion in problems. Patients treated with risk variety in continuity with probability of death. The patients lived with uncertainty. Consequently these resulted immersion in problems with four sub-categories including: (a) Physical problems, (b) money worries, (c) life disturbances, and (d) emotional strain. Conclusion: HSCT patients live in a state of limbo between life and death with multidimensional problems. Establish centers for supporting and educating of patients and their families, education of health care providers, enhancement of public knowledge about HSCT along with allocating more budgets to take care of these patients can help patients for passing from this limbo. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/447 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/447/350

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 7 3 2013 09 15 34 40 Najmaldin Saki Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Mohammad Ali Jalalifar Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Masoud Soleimani Department of Hematology and Blood Banking, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Saeideh Hajizamani Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Fakher Rahim Toxicology Research Center, Ahvaz University of Medical Sciences, Ahvaz, Iran. 2015 10 14 Stem cell therapy could have great potential for the treatment of a wide variety of diseases. Stem cells might have the ability to differentiate into a widespread cell types, and to repopulate and revitalize the damaged cells with healthy tissue, and improve its performance. We provide here the evidence supporting the critical use of stem cell as a treatment in disease conditions existing with high glucose complaint such as diabetes. The reduction of glucose stimulated cell proliferation and high glucose enhanced apoptosis in rat model, which may be a problem in therapeutic strategies based on ex vivo expansion of stem cell, and may also propagate the development of osteoporosis in high glucose complaint such as diabetes. This leads to the hypothesis that, high glucose could be more deleterious to stem cell therapy that may be due to the aggravation of oxidative stress triggered by high glucose. These findings may help to understand the possible reasons associated with high glucose induced detrimental effects on stem cells as well as provide novel therapeutic strategies for preventing the adverse effects of glucose on the development and progression of stem cells in patients with diabetes. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/446 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/446/351

https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/211 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/211/204

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 2 2009 06 15 21 26 Kamran Alimoghaddam Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran L Moezzi Faculty of Paramedical Sciences, Tehran University of Medical Sciences, Tehran, Iran Hamid Ghaffari Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran Alireza Arjmand Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran P Ghodsi Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran Bahram Chahardouli Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran S Shahrokhi Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran Ardeshir Ghavamzadeh Hematology-Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran 2015 10 01 Introduction: Hematopoietic stem cells are always in a quiescence state. Since they need retroviral transduction to infect dividing cells, they are resistant to retrovirus transduction. They need to be pre-stimulated by a cytokine cocktail. For proliferation without maturation, we suggest MIP-1α as a novel factor. Material and methods: Retroviral vector produced by PG13/LN C8 cells titter on Hela cells. Then, the CD34+ cells of cord blood can be pre-stimulated in a serum- free media supplemented with SCF, Flt3,TPO,IL6 in the presence and absence of 50 ng/ml MIP-1α. Transduction efficiency was assessed by a semi-quantitative PCR for the neomycin gene. Results: A PCR analysis of the neomycin gene in CD34+ cells revealed an improved transduction of cord blood cells in the presence of MIP-1α 65%, in comparison to its absence: 40.7%. Conclusion: the addition of MIP-1α to the cytokine cocktail improves the transduction efficiency of cord blood hematopoietic progenitor cells. Further studies are required to clarify its effect on the functional properties of CD34+ cells. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/212 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/212/205

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 3 2 2009 06 15 27 30 Shahrbanou Keyhanian Oncology- Hematology Department, School of Medicine, Islamic Azad University, Tonekabon, Mazandaran, Iran O Taziki Nephrology Department, Medical University of Mazandaran MM Saravi Radiology Department, Imam Sajjad Hospital, Ramsar, Mazandaran, Iran Z Fotokian School of Nursing and Midwifery, Ramsar, Babol Medical Sciences university, Mazandaran, Iran 2015 10 01 Introduction: Chemotherapeutic drugs used to treat cancer may cause nausea and emesis by inducing the release of 5-hydroxytryptamine (5-HT) in the small intestine. Blockage of 5-HT3 receptors in the small intestine by 5-HT3 receptor antagonists might prevent the nausea and vomiting associated with chemotherapy for cancer. The aim of this study was to compare the efficacy and tolerability of the 5-HT3 receptor antagonists (granisetron) and granisetron plus dexamethasone in the treatment of acute chemotherapy induced digestive emesis and nausea. Materials and Methods: Patients on their first course of emetic chemotherapy (cisplation or doxorubicin based regimen) were randomly placed into two treatment groups. Group A received a one-tim